Physician profile
Shahid P Malik
NPI 1588635312
$13,760.06
in general payments reported to CMS, 2019-2025
78 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,085 · 2020: $1,191 · 2021: $3,716 · 2022: $2,378 · 2023: $2,262 · 2024: $1,872 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,936 · Education: $286 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,936.44 |
| Education | $286.35 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,851.56 | 2019-2025 | |
| Amgen INC. | $883.93 | 2019-2023 | Lumakras, Vectibix, Nplate |
| Janssen Biotech, INC. | $772.21 | 2019-2024 | Darzalex, Imbruvica, Tecvayli |
| Bayer Healthcare Pharmaceuticals INC. | $633.79 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $574.28 | 2019-2024 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $562.97 | 2019-2024 | Opdivo |
| Incyte Corporation | $534.87 | 2019-2025 | Jakafi, Monjuvi |
| Astrazeneca Pharmaceuticals LP | $527.98 | 2019-2025 | Imfinzi |
| Genzyme Corporation | $464.04 | 2019-2024 | |
| Genentech USA, INC. | $347.17 | 2019-2024 | Alecensa, Tecentriq, Rozlytrek |
| Seagen INC. | $325.15 | 2020-2023 | Tukysa |
| Astellas Pharma US INC | $324.33 | 2019-2024 | Xospata, Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.08 | 2019-2024 | Gilotrif |
| Celgene Corporation | $285.59 | 2019-2024 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $277.11 | 2021-2024 | Libtayo |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahid Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.